ANGIOTENSIN-II RECEPTOR HETEROGENEITY

被引:70
作者
HERBLIN, WF
CHIU, AT
MCCALL, DE
ARDECKY, RJ
CARINI, DJ
DUNCIA, JV
PEASE, LJ
WONG, PC
WEXLER, RR
JOHNSON, AL
TIMMERMANS, PBMWM
机构
[1] The Du Pont Merck Pharmaceutical Company, Experimental Station, Wilmington, DE, 19880-0400
[2] The Du Pont Merck Pharmaceutical Company, Wilmington, DE
关键词
ANGIOTENSIN-II; ANGIOTENSIN RECEPTORS; RENIN-ANGIOTENSIN SYSTEM; ANGIOTENSIN-II BINDING INHIBITION;
D O I
10.1093/ajh/4.4.299S
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The possibility of receptor heterogeneity in the angiotensin II (AII) system has been suggested previously, based on differences in K(d) values or sensitivity to thiol reagents. One of our earliest indications was the frequent observation of incomplete inhibition of the binding of AII to adrenal cortical membranes. Autoradiographic studies demonstrated that all of the labeling of the rat adrenal was blocked by unlabeled AII or saralasin, but not by DuP 753. The predominant receptor in the rat adrenal cortex (80%) is sensitive to dithiothreitol (DTT) and DuP 753, and is designated AII-1. The residual sites in the adrenal cortex and almost all of the sites in the rat adrenal medulla are insensitive to both DTT and DuP 753, but were blocked by EXP655. These sites have been confirmed by ligand binding studies and are designated AII-2. The rabbit adrenal cortex is unique in yielding a nonuniform distribution of AII-2 sites around the outer layer of glomerulosa cells. In the rabbit kidney, the sites on the glomeruli are AII-1, but the sites on the kidney capsule are AII-2. Angiotensin III appears to have a higher affinity for AII-2 sites since it inhibits the binding to the rabbit kidney capsule but not the glomeruli. Elucidation of the distribution and function of these diverse sites should permit the development of more selective and specific therapeutic strategies.
引用
收藏
页码:S299 / S302
页数:4
相关论文
共 9 条
[1]  
Chiu A.T., Herblin W.F., McCall D.E., Et al., Identification of angiotensin II receptorsubtypes, Biochem Biophys Res Comm, 165, pp. 196-203, (1989)
[2]  
Chiu A.T., McCall D.E., Nguyen T.T., Et al., Discrimination of angiotensin II receptor sub types by dithiothreitol, Eur J Pharmacol, 170, pp. 117-118, (1989)
[3]  
Timmermans P., Wong P.C., Chiu A.T., Herblin W.F., Nonpeptide angiotensin II receptor antagonists, Trends Pharmacol Sci (In Press)
[4]  
Kamber M., De B., Gasparo M., Preliminary biochemical characterization of two angiotensin II receptor subtypes, Biochem Biophys Res Comm, 163, pp. 284-291, (1989)
[5]  
Chang R., Lotti V.J., Two distinct angiotensin II receptor binding sites in rat adrenal revealed by new selective nonpeptide ligands, Mol Pharm, 37, pp. 347-351, (1990)
[6]  
Chiu A.T., Duncia J.V., McCall D.E., Wong P.W., Et al., Nonpeptide angiotensin II receptor antagonists. Ill Structure-function studies, J Pharmacol Exp Ther, 250, pp. 867-874, (1989)
[7]  
Gehlert D.R., Speth R.C., Wamsley J.K., Distribution of [125I]angiotensin II binding sites in the rat brain: A quantitative autoradiographic study, Neuroscience, 18, pp. 837-856, (1986)
[8]  
Himeno A., Nazarali A.J., Saavedra J.M., Quantitative in vitro autoradiographic characterization of [125I]angioten-sin II binding sites in rat adrenal gland, Reg Peptides, 23, pp. 127-133, (1988)
[9]  
Speth R.C., Kim K.H., Discrimination of two angiotensin II receptor subtypes with a selective agonist analogue of angiotensin II, p-aminophenylalanine6 angiotensin II, Biochem Biophys Res Comm, 169, pp. 997-1006, (1990)